Y-90 clivatuzumab tetraxetan - Immunomedics
Alternative Names: 90Y-clivatuzumab tetraxetan; 90Y-hPAM4; 90y-Hpama4; Clivatucyn; Clivatuzumab; Clivatuzumab tetraxetan; Clivatuzumab tetraxetan Y-90; Clivatuzumab Y-90; hPAM4-Cide; hPAM4-DOTA; Humanised monoclonal antibody PAM4 Y-90; IMMU-107; Monoclonal antibody PAM4-Y-90; Pan-Cide; Y-90 clivatuzumab; Yttrium-(90Y) clivatuzumab tetraxetan; Yttrium-90 clivatuzumab tetraxetan; Yttrium-90 labelled monoclonal antibody PAM4Latest Information Update: 27 Oct 2020
At a glance
- Originator Immunomedics
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pancreatic cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 18 Jan 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy) in USA and Germany (IV), because not listed on Immunomedics pipeline, January 2018
- 18 Jan 2018 Discontinued - Phase-III for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Poland, France, Belgium, Israel, Canada, Spain, Austria and USA (IV), further to negative results from the PANCRIT® 1 trial